ImmunoGen
在场
是其中之一......
ImmunoGen 是一家在股票代码 IMGN (US) 下上市的公司。
涉及ImmunoGen的并购和融资。
- AbbVie has announced the acquisition of ImmunoGen (公布2023十一月30号).
高管
查看带有其 23 名主要高管的组织结构图
ImmunoGen 搜索最多的简介
- Mark Enyedy, Director, Chief Executive Officer and President
- Stephen McCluski, Chairman of the Board
- Dean Mitchell, Director
高管在ImmunoGen变化
- Lauren White已作为Senior Vice President and Chief Financial Officer加入公司 (新闻发布的2023九月19号).
- Michael Vasconcelles 曾任 Executive Vice President, Research, Development and Medical Affairs, 现升职为 Chief Medical Officer (新闻发布的2023七月31号).
- Anna Berkenblit, Senior Vice President and Chief Medical Officer, 已经离开公司 (新闻发布的2023七月31号).
创建提醒
跟踪 ImmunoGen 的高管变动
生物技术
ImmunoGen 拥有 2,276 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Adaptive Phage Therapeutics (美国(美洲))。
Popular M&A news in 生物技术
- Histogen has filed for bankruptcy protection (公布2024四月19号).
- Bruker has announced the acquisition of NanoString Technologies (公布2024四月18号).
- Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences (公布2024四月16号).
生物技术 行业的其他推荐联系人
消息
ImmunoGen 的最新新闻稿
- ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ImmunoGen, Inc.
- ImmunoGen Reports Recent Progress and Second Quarter 2022 Financial Results | ImmunoGen, Inc.
- ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2022 Operating Results | ImmunoGen, Inc.
- ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ImmunoGen, Inc.
- ImmunoGen Announces Research Collaboration with Oxford BioTherapeutics to Develop Novel Antibody-Drug Conjugates | ImmunoGen, Inc.
- ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ImmunoGen, Inc.
- ImmunoGen Presents Additional Efficacy and Safety Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ASCO | ImmunoGen, Inc.
- ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences | ImmunoGen, Inc.
- ImmunoGen Announces Acceptance of Biologics License Application for Mirvetuximab Soravtansine in Ovarian Cancer by US Food and Drug Administration with Priority Review | ImmunoGen, Inc.
- ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming H.C. Wainwright Global Investment Conference | ImmunoGen, Inc.
- View more press releases Close
通过电子邮件
